Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alteplase - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Alteplase - Boehringer Ingelheim

Alternative Names: Actilyse; Activacin; Activase; Cathflo; G-11021; G-11035; G-11044; GMK-527; GRTPA; IV rt-PA; Recombinant tissue plasminogen activator - Boehringer; RG-3626; rt-PA - Boehringer; rTPA - Boehringer; t-PA - Boehringer; Tissue plasminogen activator - Boehringer; Tissue type plasminogen activator - Boehringer

Latest Information Update: 22 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Genentech; John Hopkins University; Washington University School of Medicine
  • Class Anti-ischaemics; Antihaemorrhagics; Antithrombotics; Cardiovascular therapies; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Fibrinolytic agents; Plasminogen activator stimulants; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Catheter thrombosis; Myocardial infarction; Pulmonary embolism; Stroke
  • Phase III Deep vein thrombosis; Haemorrhage
  • Phase II/III SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 25 Jul 2022 Boehringer Ingelheim completes a phase II/III trials in SARS-COV-2 acute respiratory disease in Belgium, Austria, Netherlands, Turkey, Spain, Russia, Romania, Portugal, Poland, Mexico, Malaysia, Italy, India, Germany, France, Denmark, Brazil (IV, Infusion) (NCT04640194) (EudraCT2020-002913-16)
  • 30 Sep 2021 Genentech in collaboration with Denver Health and Hospital Authority completes a phase II clinical trials in SARS-COV-2 acute respiratory disease in USA (IV) (NCT04357730)
  • 04 Aug 2021 Assistance Publique - Hôpitaux de Paris in collaboration with Boerhinger Ingelheim initiates the phase III PEITHO-3 trial in Pulmonary embolism in Austria, France and Germany (NCT04430569) (EudraCT2018-000816-96)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top